GlassScriptPhysician profile
Anna Dubyanskite
NPI 1134230923
$3,984.03
in general payments reported to CMS, 2019-2025
27 companies · $892 in 2025
The $892 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $257 · 2021: $231 · 2022: $915 · 2023: $601 · 2024: $816 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,306 · Education: $2.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,306.31 |
| Education | $2.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $1,105.25 | 2019-2025 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $645.64 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $426.31 | 2020-2025 | Rayaldee |
| Amgen INC. | $240.51 | 2019-2025 | Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $217.92 | 2019-2024 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $199.95 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $189.43 | 2024-2025 | Tarpeyo |
| Lilly USA, LLC | $142.97 | 2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $131.97 | 2020-2025 | Voyxact, Jynarque |
| Glaxosmithkline, LLC. | $103.70 | 2020-2023 | Benlysta |
| Scpharmaceuticals INC. | $84.05 | 2025 | |
| Mallinckrodt Hospital Products INC. | $63.61 | 2021 | |
| Fresenius USA Marketing, INC. | $56.59 | 2019-2024 | Velphoro |
| Amag Pharmaceuticals, INC. | $48.53 | 2021-2022 | |
| Genzyme Corporation | $47.88 | 2019-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $44.11 | 2020-2024 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.78 | 2023-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $33.10 | 2019-2021 | |
| Nxstage Medical, INC. | $23.76 | 2024 | |
| Xeris Pharmaceuticals, INC. | $23.23 | 2022 | |
| Arbor Pharmaceuticals, INC. | $23.19 | 2020 | |
| Aurinia Pharma U.S., INC. | $18.58 | 2025 | Lupkynis |
| Travere Therapeutics, INC. | $17.53 | 2023-2025 | Filspari |
| Akebia Therapeutics INC | $17.11 | 2020 | |
| Alnylam Pharmaceuticals INC. | $15.96 | 2024 | Oxlumo |
| Pfizer INC. | $14.84 | 2021 | |
| Horizon Therapeutics Plc | $14.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Dubyanskite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.